PMC8545975_01
Endpoints, (A) Primary outcome for the incidence of total bleeding (HR 0.930; 95% CI, 0.635 to 1.361; P = 0.7088); (B) secondary outcome for the incidence of major bleeding (HR, 0.273; 95% CI, 0.057 to 1.315; P = 0.1056) HR, hazard ratio. Dual therapy: ticagrelor therapy group; triple therapy: clopidogrel plus aspirin group.
fcvm-08-745549-g0002.jpg
PMC8545975_01_fcvm-08-745549-g0002.jpg
F2
Triple group experienced bleeding events. The time-to-first bleeding event analysis revealed comparable bleeding rates between the 2 groups [hazard ratio (HR), 0.930; 95% CI, 0.635 to 1.361; P = 0.7088] (Figure 2A). Similarly, 7 (4.73%) patients in the ticagrelor therapy group and 2 (1.37%) patients in the Triple group experienced major bleeding events (HR, 0.273; 95% CI, 0.057 to 1.315; P = 0.1056) according to the TIMI bleeding classifications (Figure 2B).
(A) Primary outcome for the incidence of total bleeding in PPS (N = 247) (HR, 0.889; 95% CI, 0.593 to 1.332; P = 0.5684); (B) Secondary outcome for the incidence of major bleeding (HR, 0.313; 95% CI, 0.063 to 1.552; P = 0.1550). HR, hazard ratio. Dual therapy: ticagrelor therapy group; triple therapy: clopidogrel plus aspirin group.
fcvm-08-745549-g0003.jpg
PMC8545975_01_fcvm-08-745549-g0003.jpg
F3
Table 2). Considering the secondary endpoints in the PPS, 6 (4.96%) patients in the ticagrelor therapy group experienced major bleeding events, whereas 2 (1.59%) patients in the Triple therapy group experienced major bleeding events. Time-to-event analysis showed no significant difference (HR, 0.313; 95% CI, 0.063 to 1.552; P = 0.1550) (Figure 3A; Supplementary Table 2) between the 2 groups.
Incidence of cardiovascular event outcomes of the 2 groups (HR, 0.845; 95% CI, 0.488 to 1.465; P = 0.5484). HR, hazard ratio. Dual therapy: ticagrelor therapy group; triple therapy: clopidogrel plus aspirin group.
fcvm-08-745549-g0004.jpg
PMC8545975_01_fcvm-08-745549-g0004.jpg
F4
Cardiovascular events, including re-PCI, surgical bypass, MI, heart failure, rehospitalization due to angina pectoris, stent thrombosis and death due to cardiovascular causes, at the end of the 6-month follow-up are shown in Figure 4; Table 4.
Incidence of cardiovascular event outcomes of the two groups (PPS, N = 247) (HR, 0.844; 95% CI, 0.461 to 1.547; P = 0.5836). HR, hazard ratio. Dual therapy: ticagrelor therapy group; triple therapy: clopidogrel plus aspirin group.
fcvm-08-745549-g0005.jpg
PMC8545975_01_fcvm-08-745549-g0005.jpg
F5
Triple group. Time-to-event analysis showed no significant difference (HR, 0.844; 95% CI, 0.461 to 1.547; P = 0.5836) (Figure 5; Supplementary Table 3) between the 2 groups.